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Abstract
The rapid emergence and dissemination of antibiotic-
resistant microorganisms in ICUs worldwide threaten
adequate antibiotic coverage of infected patients in
this environment. The causes of this problem are
multifactorial, but the core issues are clear: the
emergence of antibiotic resistance is highly correlated
with selective pressure resulting from inappropriate
use of these drugs. Because a significant increase in
mortality is observed when antibiotic therapy is
delayed in infected ICU patients, initial therapy
should be broad enough to cover all likely pathogens.
Receipt of unnecessary prolonged broad-spectrum
antibiotics, however, should be avoided. Local
microbiologic data are extremely important to
predict the type of resistance that may be present
for specific causative bacteria, as is prior antibiotic
exposure, and antibiotic choices should thus be made
at an individual patient level.
Background
ICU patients are particularly at risk of developing infec-
tions with multidrug-resistant (MDR) organisms, which
are more prevalent in this environment. Appropriate
and adequate antibiotic coverage is essential in the treat-
ment of these patients. In the present update, we will
discuss the mechanisms of development of resistance,
before highlighting some of the key issues related to
antibiotic management and possible approaches to pre-
vent further development of resistance.
Epidemiology
There is a general increase in the number of resistant
microorganisms worldwide, although specific patterns
vary considerably across countries. There has been a
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significant increase across Europe in the percentages of
Klebsiella pneumoniae resistant to fluoroquinolones,
third-generation cephalosporins, and aminoglycosides, as
well as combined resistance to all three antibiotic groups
[1]. Escherichia coli resistance to third-generation cepha-
losporins has also increased significantly, from 9.6 % to
12.0 % between 2011 and 2014 (population-weighted
European Union/European Economic Area (EU/EEA)
mean percentage of resistance) [1]. For Acinetobacter
species, there is considerable variability in resistance rates,
but high percentages (>50 %) of isolates with combined
resistance to fluoroquinolones, aminoglycosides, and car-
bapenems have been reported from southern Europe
(Fig. 1). Although the percentage of methicillin-resistant
Staphylococcus aureus (MRSA) decreased between 2011
and 2014, this decrease was less pronounced compared
with the previous 4-year period. In 2014, the EU/EEA
population-weighted mean MRSA percentage remained
high, with seven out of 29 reporting countries having
MRSA percentages >25 %.
The increased prevalence of carbapenem-resistant
Enterobacteriaceae (CRE), particularly in K. pneumoniae
which has seen near untreatable infections occurring in
an increasing number of hospitals, is also of concern.
Greece, Italy, and Malta in Europe, the USA, South
America, and Asia have notably been affected by these
bacteria [2, 3]. Such is the level of threat that the US
Centers for Disease Control and Prevention has named
CRE as one of the top three most urgent antimicrobial-
resistant challenges [4].
Mechanisms of resistance
Resistance can occur in all types of pathogens encoun-
tered in the ICU setting, although Gram-negative bac-
teria are the most likely to exhibit resistance to multiple
classes of antibiotics. The three most representative
mechanisms of resistance to β-lactam antibiotics in
Gram-negative bacteria are: destruction of antibiotics by
β-lactamases; impermeability, including closure of porin
channels in the bacterial cell wall (most notable as the
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mechanism of resistance to carbapenems for Pseudo-
monas aeruginosa); and extrusion of antibiotics by efflux
pumps (which can lead to resistance to multiple classes of
antibiotics). Analogous mechanisms of resistance occur
with classes of antibiotics that are increasingly being used
to manage infections due to bacteria resistant to β-lactam
antibiotics (Table 1). By contrast to β-lactam antibiotics,
which have their mechanisms of action and resistance
located within the cell wall of the bacteria, the location of
binding sites and modifying enzymes of the other
antibiotic classes described in Table 1 are intracellular.
Knowledge of this variability of action and resistance
mechanisms can contribute to informed decisions in the
selection of antimicrobial therapy for resistant organisms.
Extended-spectrum β-lactamases (ESBLs) are broad-
spectrum enzymes produced most characteristically by
Fig. 1 Acinetobacter species: percentage of invasive isolates with combined resistance to fluoroquinolones, aminoglycosides, and carbapenems.
European Union/European Economic Area, 2014. From [1]
Table 1 Mechanisms of resistance in classes of antibiotics used to treat resistant pathogens
Permeability [55] Enzymatic destruction Altered binding sites Efflux [57]
β-lactams [32] ✓ ✓ ✓ ✓
β-lactamases Penicillin-binding proteins
Fluoroquinolones [56] ✓ ✓ ✓
Alterations in DNA gyrase and topoisomerase IV
Protection by plasmid-mediated Qnr protein
Aminoglycosides [58] ✓ ✓ ✓ ✓
Adenolyating and acetylating enzymes 30S ribosomal subunit
Tetracyclines [59] ✓ ✓ ✓ ✓
Modification enzymes 70S ribosomal subunit
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E. coli, Klebsiella, and Proteus species (Table 2). Repre-
sentative of the ease with which resistance can occur,
these enzymes may develop on the basis of a change in
only one amino acid in the β-lactamases normally
produced [5]. Despite the minimal structural change,
ESBLs have the capacity to inactivate many broad-
spectrum β-lactam drugs. It is noteworthy that use of
third-generation cephalosporins and fluoroquinolones
has been identified as a risk factor for selection of ESBLs
[6, 7]. Of the clinically relevant attributes of these en-
zymes, ESBLs represent a classic example of a resistance
mechanism in which in vitro susceptibility may not be
consistently predictive of clinical efficacy.
By contrast to the plasmid-mediated production of
ESBLs, AmpC β-lactamases most classically are
chromosomally-mediated and occur in such important
ICU pathogens as P. aeruginosa and Enterobacter spe-
cies. In recent years, however, plasmid-mediated
AmpC β-lactamases have been identified in pathogens
such as E. coli and K. pneumoniae. Influencing the
risk that antibiotics pose for the selection of infection
caused by resistant pathogens is the fact that one in
every 106–107 organisms with the characteristic po-
tential for AmpC β-lactamase production (listed in
Table 2) has a spontaneous mutation that allows it to
produce this enzyme [8]. These mutant strains are
not naturally competitive and do not, therefore, over-
grow to destroy the sensitive nonmutant flora. How-
ever, when antibiotics are given that destroy the
sensitive flora, the resistant mutant strains can prolif-
erate and establish themselves as the predominant
pathogens. In such a scenario, injudicious use of
broad-spectrum agents may lead to the development
of clinical resistance during therapy.
There has been considerable recent publicity about a
study from China that has described the first strains of
E. coli with plasmid-mediated colistin resistance [9]. Al-
though there are concerns about the use of colistin, in-
cluding toxicity and dosing uncertainties, it is one of a
very few alternatives that can be used in some cases to
treat infections caused by CRE. This novel mechanism
of colistin resistance, previously only chromosomally
mediated, is of grave concern given that strains harbor-
ing the plasmids are already widely prevalent in animals
in China, and also (albeit lesser so) in some clinical
isolates.
Carbapenemase production by Gram-negative bacteria
is one of the most concerning patterns of resistance
encountered in the ICU because it is associated increas-
ingly with resistance to all presently marketed antibiotics.
Using the Ambler classification of β-lactamases—in which
there are Classes A, B, C, and D—carbapenemases occur
within three of the four classes. Class B β-lactamases have
a metallo base, and the initial carbapenemases described
clinically were Class B metallo-enzymes. A representative
example from clinical practice of a Class B metallo-
enzyme is the New Delhi metallo-β-lactamase, which is
found in certain Enterobacteriaceae. Ambler Class A
β-lactamases are serine based and include the majority of
ESBLs. Carbapenemases produced by K. pneumoniae
were identified within this Ambler class and subse-
quently characterized as K. pneumoniae carbapene-
mases (KPCs). Gaining increasing importance today
are the Class D serine-based carbapenemases, with
the most classic being the oxa-type enzymes produced
by organisms such as Acinetobacter species. Even
though the name carbapenemase identifies the ability
of these enzymes to inactivate carbapenem antibiotics,
carbapenemases are not specific for carbapenem anti-
biotics but have the ability to hydrolyze β-lactams of
all classes [10].
Links between antibiotic prescribing and resistance
Most of the time, antibiotics do not create resistance per
se. Antibiotic resistance determinants have been circu-
lating within the microbial genome for millennia, largely
predating the manufacture and use of antibiotics by hu-
man beings [11, 12]. This was conclusively demonstrated
Table 2 A clinical approach to β-lactamases
Type of β-lactamase Classic microorganisms or types Clinical prescribing challenges
Extended-spectrum β-lactamases Escherichia coli
Klebsiella species
Proteus species
Variability of in vitro activity consistently predicting in vivo efficacy
Collateral damage of selection by certain antibiotic classes
AmpC Serratia species
Pseudomonas aeruginosa
Indole + Proteus
Citrobacter species
Enterobacter species
Collateral benefit of possibly preventing selection of resistance
by limiting antibiotics with activity against certain bacteria
(as an example, pseudomonal-sparing antibiotic regimens)
Carbapenemases KPC (Ambler Class A)
NDM (Ambler Class B)
Oxa-typea (Class D)
Selection risk by intensity and duration of prior antibiotic therapy
Consideration of the role of combination therapy in treatment
aMost characteristically found in Acinetobacter
KPC Klebsiella pneumoniae carbapenemase, NDM New Delhi metallo-β-lactamase (found in Enterobacteriaceae)
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by D’Costa et al. [12] using targeted metagenomic ana-
lyses of rigorously authenticated ancient DNA from
30,000-year-old permafrost sediments and the identifica-
tion of a highly diverse collection of genes encoding re-
sistance to β-lactam, tetracycline, and glycopeptide
antibiotics, very similar to the genes currently expressed
by bacteria in healthcare-associated infections. The
emergence and dissemination of resistant microorgan-
isms during antimicrobial therapy is thus essentially
driven by the selection of the small fraction of naturally
resistant bacteria that exist in all microbiota, because of
the pressure they exert on the susceptible microorgan-
isms, giving a survival advantage to the cells that are in-
trinsically resistant to the antimicrobial agent(s) used. In
ICU patients, this phenomenon is not only operational
at the level of the infected site but also at the level of the
digestive tract microbiota and other commensal floras,
where the huge number of bacteria present may very
rapidly promote the emergence of drug-resistant micro-
organisms. Even if these bacteria do not themselves
cause disease, they can easily share these resistance
genes with bacteria that do, through direct exchange of
DNA (by conjugation or extrachromosomal plasmid
DNA). One recent study confirmed that short exposure
to imipenem in ICU patients was followed by a signifi-
cant increase in carriage of imipenem-resistant Gram-
negative bacilli [13]. The risk of acquisition was 5.9
times higher in patients who received only 1–3 days of
imipenem treatment compared with controls, and in-
creased to 7.8 times higher in those who received longer
treatments.
Numerous studies in human and veterinary medicine
have shown a correlation between consumption of anti-
microbials and resistance in bacteria isolated from
infected humans [14–19]. Recent studies have also con-
firmed the direct effect of antibiotic use in selecting re-
sistant organisms at the individual level. For example,
Malhotra-Kumar et al. [20] demonstrated in a double-
blind, randomized trial performed in a large group of
healthy volunteers that macrolide exposure for 7 days
led directly to the emergence of resistance in the oral
streptococcal flora.
In addition to the selection pressure they exert on sus-
ceptible bacteria, antibiotics can influence antibiotic re-
sistance through several other mechanisms, including
changes in cell permeability and efflux or alterations in
the antibiotic target, and horizontal transfer of resistance
genes [21]. Many antibiotics, even at very low concentra-
tions that cannot kill susceptible bacteria, induce the
formation of reactive oxygen species (ROS), which can
damage bacterial DNA, increasing genetic variability
[22]. Selection of hypermutable clones is another un-
desirable consequence that can enhance resistance
development.
The potential to select resistant strains of P. aerugi-
nosa with antibiotics that have activity against P. aerugi-
nosa has been demonstrated repeatedly in the medical
literature [23, 24]. What has evolved from this risk of
selecting resistance is the concept of stratifying therapy
for infections based on the likelihood of the presence or
absence of P. aeruginosa as the etiologic agent of the in-
fection, and this has been a core consideration in mul-
tiple clinical guidelines [25, 26].
There are numerous reports of carbapenemase out-
breaks linked to various classes of antibiotics. In contrast
to establishing a link to only one specific class of antibi-
otics, there is an evolving body of medical literature
suggesting an important relationship between prior anti-
microbial therapy and the subsequent identification of
carbapenemase-producing bacteria. In a 4-year case–
control study of 102 patients, the only covariate independ-
ently associated with CRE in all multivariate analyses was
the cumulative number of prior antibiotic exposures [27].
A 26-month case–control study (96 ESBL-carbapenem-
resistant K. pneumoniae and 55 ESBL-carbapenem-
sensitive K. pneumoniae) from Greece identified both
prior cumulative exposure to antibiotics and increasing
duration of prior treatment as risk factors [28]. Antibiotic
treatments shown in this study to be associated with the
isolation of carbapenemases were therapy with β-lactam/
β-lactamase inhibitor or with a combination of fluoro-
quinolone and carbapenem. These data are consistent
with previous reports that no particular class of antibiotic
is the predominant predisposing factor for selection of
carbapenemase production, but that it is rather the inten-
sity and duration of antibiotic therapy which are the most
important variables in creating the milieu in which
carbapenemase-producing bacteria are selected.
Management: patient stratification and antibiotic
choices
Perhaps the greatest challenge imposed by MDR Gram-
negative bacteria is attainment of the appropriate degree
of balance between efficacy and ecology. It is well recog-
nized that there are significant increases in mortality
rates when antibiotic therapy is delayed [29, 30], challen-
ging the clinician to prescribe therapy broad enough to
cover all of the most likely pathogens. What is simultan-
eously recognized is the collateral damage of selecting
resistant bacteria that can occur with prolonged receipt
of broad-spectrum antibiotics [31].
Three important categories can influence antimicrobial
choices: patient characteristics; risk factors for infection
with specific pathogens; and severity of illness. Of the
demographic data of patients with infections, advanced
age and comorbid illnesses have been associated with
decreased reserve and, hence, an increase in mortality.
Contact with the health care system is an important
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patient characteristic that influences the broadness of
initial antibiotic therapy. Previous hospitalization (within
the past 30 days as a defining feature of hospital-
acquired infection and within the past 90 days as a
defining feature of healthcare-associated infection) in-
creases the risk of infection by a resistant pathogen that
was acquired in the healthcare environment. Invasive
procedures, even those occurring in the outpatient set-
ting, increase the risk of colonization by MDR organ-
isms, with such colonization serving as an antecedent
predisposition to infection with MDR microorganisms.
Local microbiologic data are extremely important in pre-
dicting the type of resistance that may be present in the
etiologic agent causing a clinical infection. It is import-
ant to recognize that such local data may vary from unit
to unit within a hospital, and when possible unit-specific
data are optimal. In recognition of the fact that resist-
ance can rapidly develop within a practice environment,
it is important that microbiologic data should be as
current as possible. Antibiograms reporting data that are
from a previous year may be many months behind what
is presently occurring. Very important is the role of prior
antibiotic exposure, recognizing the risk of eliminating
normal flora and allowing the selection of resistant bac-
teria. Although various timelines have been suggested in
the medical literature about what defines “recent” anti-
biotic therapy, within the previous 90 days is a consist-
ently cited number. A second element of importance in
stratification regarding antibiotic therapy is the likely
type of microorganism. As noted previously, risk
stratification related to P. aeruginosa has been in-
cluded in multiple clinical guidelines [25, 26]. Of all
the variables that influence stratification of patients
into a category requiring coverage of MDR bacteria,
severity of illness may be the most important. As se-
verity of illness increases, the margin for error in ini-
tial antimicrobial therapy diminishes and this requires
consideration of coverage against multiple patterns of
bacterial resistance.
Since the reviews by Jacoby and Munoz-Price [32] and
by Paterson and Bonomo [5] listing carbapenems as
drugs of choice for infections caused by ESBL-producing
bacteria, this class of antibiotics has been considered
first-line therapy for such infections. This recommenda-
tion is influenced by the fact that ESBL-producing
pathogens are often resistant to fluoroquinolones and
aminoglycosides since resistance mechanisms for these
classes of antibiotics are often carried on the same large
plasmids that contain the genetic elements for ESBL
production. Paradoxically, even though carbapenems are
β-lactam agents, they are stable in the presence of
ESBLs. More recently and in response to a large volume
of infections in Spain caused by ESBL-producing
bacteria, a group of investigators from that country
conducted a post hoc analysis of patients with blood-
stream infections due to ESBL-producing E. coli from
six published prospective cohorts [33]. In this trial, mor-
tality and length of hospital stay were compared in pa-
tients treated with either amoxicillin–clavulanic acid
(AMC) or piperacillin–tazobactam (PTZ) versus those
receiving a carbapenem. In this analysis, the infection
source was the urinary or biliary tract in two-thirds of
the patients. The results suggest that AMC and PTZ are
suitable alternatives to carbapenems for treating patients
with bloodstream infections due to ESBL-producing
E. coli if there is in vitro activity. However, the vari-
able in vitro susceptibility of ESBL-producing bacteria
to β-lactam/β-lactamase inhibitor combinations war-
rants consideration before these agents are used as
empiric therapy for serious infections.
Further addressing the question of whether PTZ is
clinically as efficacious as carbapenems in the treatment
of bacteremia caused by ESBL-producing organisms, in-
vestigators compared 14-day mortality when PTZ versus
a carbapenem was used as empiric therapy (defined in
this trial as antibiotic therapy administered to a patient
before their ESBL status was known) in a cohort of 331
patients with ESBL bacteremia who received definitive
therapy with a carbapenem [34]. The adjusted risk of
death was 1.9 times higher for patients receiving empiric
PTZ compared with empiric carbapenem (95 % confi-
dence interval 1.07–3.45).
It is important to acknowledge that the data regarding
the role of PTZ in the treatment of ESBL-producing
bacteria may not be an accurate predictor of how
new β-lactamase inhibitors (e.g., avibactam or relebactam)
or new combinations (e.g., ceftolozane/tazobactam) may
perform in the treatment of these infections. Ceftolozane/
tazobactam in combination with metronidazole was
shown to be noninferior to meropenem in a multinational,
double-blind randomized phase 3 trial of adult patients
hospitalized with complicated intraabdominal infections
[35]. Of the isolated pathogens, 7.2 % were ESBL-
producing Enterobacteriaceae and for this group of pa-
tients clinical cure rates were 95.8 % in the ceftolozane/
tazobactam group and 88.5 % in the meropenem group.
Similar findings were reported from a randomized
trial of adult patients hospitalized with complicated
lower urinary tract infections or pyelonephritis, in which
7.6 % of the isolated pathogens were ESBL-producing
Enterobacteriaceae [36].
In a recent review, Harris et al. [37] suggested three
clinical scenarios in which β-lactam/β-lactamase inhibi-
tors might be appropriate instead of using a carbapenem
in the treatment of infections caused by ESBL-producing
organisms: urinary tract infections (including with
bacteremia); nonurinary tract infections in which the
isolate is susceptible at a low minimum inhibitory
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concentration (MIC); and when adequate source control
has been achieved.
In a retrospective study of monomicrobial bacteremia
caused by ESBL-producing organisms, patients were
definitively treated with cefepime if there was in vitro
activity to that antibiotic or with a carbapenem [38]. Pa-
tients who received cefepime as definitive therapy were
more likely to have clinical failure, and the survival ana-
lysis consistently found that individuals who received ce-
fepime therapy had a lower survival rate. Based on these
observations, the authors concluded that cefepime
empirical therapy was inferior to carbapenem in the
treatment of patients with bacteremia due to cefepime-
susceptible ESBL-producing bacteria. It is noteworthy
that the cefepime breakpoint for susceptibility in this
study was ≤8 μg/ml, which may have overstated the sus-
ceptibility rate, compared with the more recent break-
points of ≤2 μg/ml from the Clinical and Laboratory
Standards Institute (CLSI) and ≤1 μg/ml from the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST), which would result in lower rates
of susceptibility [39].
A major challenge in the ICU is achieving adequate
therapy for infections caused by carbapenemase-
producing bacteria. An important early observation re-
garding therapy of such infections was that monotherapy
with an agent like polymyxin might not provide optimal
efficacy. In an analysis of 15 studies and case reports of
the therapy of infections caused by KPCs, the success of
polymyxin monotherapy was 14 % in contrast to 73 %
with polymyxin combinations [40]. Considerations re-
garding such failure include the lack of optimal dosing
of polymyxin (potentially due to variables such as
augmented renal clearance in patients with severe ill-
ness) versus the lack of an additive or even synergis-
tic effect that might occur with combination therapy.
Early data suggested a potential role for carbapenems
as a therapeutic option if the MIC of the infecting or-
ganism was ≤4 mg/l and if the carbapenem was given
in combination with another active agent [41]. In an
observational study from Greece regarding the treat-
ment of infections due to carbapenemase-producing
K. pneumoniae, patients who received a carbapenem in
combination with other active agents had a mortality rate
of 19.3 % if the carbapenem MIC of the infecting organ-
ism was ≤8 μg/ml versus a mortality rate of 35.5 % if the
MIC was >8 μg/ml [42]. An overall observation in this
trial was that mortality was higher in patients who re-
ceived monotherapy than in those treated with combin-
ation regimens. In a retrospective analysis of the data
from this trial, the lowest mortality was observed in pa-
tients treated with a carbapenem-containing regimen.
However, a recent analysis of 12 retrospective cohort
studies or case series, two prospective observational
studies, and two randomized controlled trials showed
no difference in mortality between colistin alone and
colistin/carbapenem combination therapy [43]. Several
clinical trials are ongoing to further assess this issue
(ClinicalTrials.gov NCT01732250 and NCT01597973).
Until these data are available, a major challenge for
the clinician will be to interpret existing data—most
of which are observational or retrospective—and make
clinical decisions regarding the therapy for such infec-
tions. Important considerations in those analyses will
be the microbiologic data of the organism (including
the specific carbapenem MICs), the timing of the adminis-
tered antibiotics, the effectiveness of therapy based on
pharmacokinetic/pharmacodynamic considerations, and
the potential for additive or even synergistic effects with
combination therapy.
Prevention
A fundamentally important challenge in clinical medi-
cine is how to control or prevent antibiotic resistance.
Several strategies may be beneficial.
Rapid diagnostics
Rapid treatment of sepsis is associated with decreased
mortality in patients with serious infections, but diagno-
sis of sepsis can be difficult and delayed in critically ill
patients. Hence broad-spectrum empirical antibiotics are
often started before microbiology results are available,
resulting in some patients receiving unnecessary anti-
biotic treatment. More rapid, culture-independent iden-
tification methods are being developed [44], which, in
addition to providing quicker identification of the patho-
gen causing an infection, can also rapidly identify the
susceptibility patterns of the organism. The benefits of
such information are twofold: if the organism possesses
resistance mechanisms, appropriate therapy based on
susceptibilities can be more quickly accomplished; and,
based on susceptibility information, the duration of
broad-spectrum therapy may be limited. By enabling
earlier, accurate diagnosis of infection and of the causa-
tive microorganism(s), these tests may help optimize
antibiotic prescriptions, and in so doing potentially
reduce selection pressure and thus resistance.
Colonization prevention
Embracing the principle that colonization is the ante-
cedent event leading to clinical infection, the clinician is
poised to incorporate an important infection prevention
opportunity into clinical practice. In an observational co-
hort study in two ICUs with endemic carbapenemase-
producing Enterobacteriaceae, patients were screened
with perineal swabs at admission and twice-weekly
thereafter [45]. Patients colonized with carbapenemase-
producing Enterobacteriaceae had a 1.8 times greater
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hazard of dying in the ICU than noncolonized patients,
primarily because of an increased length of stay. In a
study designed to prevent colonization and infection by
KPC-producing Enterobacteriaceae in four long-term
acute-care hospitals with high endemic KPC prevalence,
a bundled intervention was tested using a stepped-
wedge design [46]. Patients were screened for rectal
KPC colonization on admission and every other week.
Contact isolation and geographic separation of KPC-
positive patients was implemented in ward cohorts or
single rooms. All patients were bathed daily with chlor-
hexidine gluconate. Healthcare workers were educated,
and their adherence was monitored. During the inter-
vention period of the study, the incidence rate of KPC
colonization fell from 4 to 2 acquisitions per 100
patient-weeks (p = 0.004 for linear decline). Compared
with the preintervention period, there were decreases in
the isolation of KPC in any clinical culture, KPC
bacteremia, and all-cause bacteremia. The demonstra-
tion that prevention of colonization can have significant
clinical benefits in the era of carbapenemase infections
has significant implications for ICU and non-ICU
settings.
Heterogeneity of antibiotic usage
The basis for this approach was noted in the mid-1990s
through a program of informatics at LDS Hospital in
Salt Lake City, UT, USA [47]. Subsequently, other
groups found that patterns of antibiotic use in which the
same antibiotic was given repeatedly (i.e., homogeneity)
were associated with higher rates of resistance than
when there was variability in the antibiotics given by the
same prescriber among patients (i.e., heterogeneity) [48].
Several studies have evaluated the role of empiric anti-
biotic rotation protocols in reducing development of
antibiotic resistance. In a surgical ICU, Bennett et al.
[49] reported that monthly cycling of four antibiotics
(PTZ, imipenem/cilastin, ceftazidime, and ciprofloxacin)
as the primary antibiotic to treat suspected Gram-
negative infections was associated with an overall im-
provement in the antibiotic susceptibility profile of
Gram-negative organisms compared with the medical
ICU in the same hospital where cycling was not per-
formed. The 2007 antimicrobial stewardship guideline
from the Infectious Diseases Society of America/Society
of Healthcare Epidemiology of America [50] stated that
there were “insufficient data to recommend the routine
use of antimicrobial cycling as a means of preventing or
reducing antimicrobial resistance over a prolonged
period of time”.
Ironically, formal cycling may impose antibiotic selec-
tion pressures during those periods when a particular
agent is preferred. However, increased diversity of pre-
scribing has been shown to correlate with reduced levels
of resistance [51]. The challenge therefore remains how
increased antibiotic heterogeneity can be achieved in a
way that delivers benefits rather than risks.
Short duration antibiotic courses
Since the classic paper in the 1980s elucidating the
concept that clinical resistance in Gram-negative
pathogens occurs on the basis of selection by antibi-
otics of spontaneously mutant strains of bacteria
which possess resistance mechanisms [8], there has
been increasing awareness about the importance of
appropriately limiting the duration of antibiotic ther-
apy. This strategy has taken two important forms in
recent years. One has been de-escalation of therapy,
in which the spectrum of empiric antibiotics is nar-
rowed when microbiological data become available to
minimize the selective pressure of antibiotics. A sec-
ond strategy has been antimicrobial stewardship,
which targets the duration of therapy as an important
means of achieving optimal clinical outcomes. Current
guidelines recommend a course of 7–10 days for most se-
vere infections [52], although some recent data support
the use of shorter courses in certain infections, such as
intraabdominal infections [53]. Many clinicians, however,
remain hesitant about prescribing fewer fixed days of anti-
biotics for patients with severe bacterial infection, and
prefer to customize antibiotic duration based on the
clinical course of the disease and/or using serial de-
terminations of a biological marker of infection, such
as procalcitonin (PCT). Adapting the antimicrobial
treatment duration to PCT kinetics has been demon-
strated as useful in several randomized trials targeting
patients with acute respiratory infection [54]. Never-
theless, PCT kinetics should only be used as a tool to
support clinical judgment.
Conclusion
There is no doubt that we are now faced with greater
antibiotic resistance challenges than ever before, limit-
ing treatment options for patients with severe infec-
tions. The rate of development of new antimicrobial
agents has failed to keep pace with the “ingenuity” of
bacteria to mutate and become resistant to antibi-
otics. We have to adapt to this threat by reducing un-
necessary antibiotic prescribing, both qualitatively and
quantitatively. We need to optimize control measures
to minimize the risk of spread of resistant bacteria,
and we have to find novel ways to detect pathogens
early. These approaches will help prevent the spread
of MDR pathogens and could enable us to direct last-
line (and in some cases, narrow-spectrum) antibiotics
more effectively to those patients who need them
most, rather than the current “broad-spectrum is best”
approaches.
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